LTR Pharma’s intranasal spray OROFLOW® has secured ethics approval for a clinical study targeting oesophageal motility disorders, marking its first foray beyond erectile dysfunction. The study, led by Dr Peter Wu, aims to validate a non-invasive alternative for swallowing difficulties in a market projected to reach US$8.1 billion by 2034.
- Ethics approval for OROFLOW® clinical study in oesophageal motility disorders
- Investigator-initiated trial led by Dr Peter Wu at St George Hospital
- Potential non-invasive alternative to surgery and invasive treatments
- OMD market forecast to hit US$8.1 billion by 2034
- Study to assess swallowing function and chest pain improvements
Ethics Approval Opens New Clinical Chapter for LTR Pharma
LTR Pharma (ASX:LTP) has taken a pivotal step by securing Human Research Ethics Committee (HREC) approval for its OROFLOW® intranasal spray to enter clinical evaluation in oesophageal motility disorders (OMD). This marks the first time the company’s proprietary intranasal platform, previously focused on erectile dysfunction, will be tested in a gastrointestinal setting. The investigator-initiated study will be led independently by Dr Peter Wu, Director of St George Motility Services, who has reported encouraging early clinical observations suggesting OROFLOW® may ease swallowing difficulties and reduce eating-related chest pain.
Targeting a Significant Unmet Need with Non-Invasive Therapy
OMD encompasses conditions like achalasia and oesophageal spasms, where impaired muscle function disrupts swallowing and causes painful contractions. Current treatments often involve invasive procedures such as surgery, pneumatic dilation, or botulinum toxin injections. OROFLOW® aims to offer a rapid-acting, non-invasive alternative via intranasal delivery of a PDE5 inhibitor, which relaxes smooth muscle and lowers oesophageal sphincter pressure. This could improve oesophageal emptying and alleviate dysphagia and chest pain, potentially restoring patients’ ability to eat normally.
Study Design to Assess Physiological and Symptomatic Effects
The PILOT study will progress in two stages, beginning with healthy volunteers to map the onset and duration of OROFLOW®’s effects, before moving to OMD patients scheduled for Peroral Endoscopic Myotomy (POEM). Researchers will measure oesophageal contractility, bolus flow timing, and distension pressure. Dr Wu emphasised the potential for a non-invasive treatment to reduce or delay the need for surgery, highlighting the importance of rigorous testing to confirm initial positive observations.
Commercial Implications Beyond Erectile Dysfunction
The global market for OMD treatments stands at an estimated US$4.5 billion in 2024, with projections reaching US$8.1 billion by 2034. Success in this clinical study could validate LTR Pharma’s intranasal platform for broader therapeutic applications, extending beyond its established products SPONTAN® and ROXUS® for erectile dysfunction. Executive Chairman Lee Rodne noted the strategic significance of this independent trial as a potential gateway to expanding the company’s commercial footprint into new indications.
Independent Study and Next Steps
The study is funded by a research grant from LTR Pharma but designed and conducted independently by Dr Wu and his team, with no additional payments beyond usual salaries. The company anticipates study initiation in the coming quarter and will monitor recruitment and data milestones closely. Investors should watch for updates on clinical outcomes, which will be crucial in determining the viability of OROFLOW® as a non-invasive treatment for a sizeable and underserved patient population.
Bottom Line?
LTR Pharma’s ethics approval for OROFLOW® in oesophageal motility disorders opens a promising new frontier but hinges on forthcoming clinical data to prove its non-invasive potential.
Questions in the middle?
- Will OROFLOW® demonstrate statistically significant improvements in swallowing and chest pain in OMD patients?
- How quickly can LTR Pharma translate clinical findings into regulatory approvals and commercial launches beyond erectile dysfunction?
- Could success in OMD pave the way for further intranasal therapies targeting other gastrointestinal or smooth muscle disorders?